Fig. 5From: Effects of Lianhuaqingwen Capsules in adults with mild-to-moderate coronavirus disease 2019: an international, multicenter, double-blind, randomized controlled trialSubgroup analysis of the therapeutic effect of the primary endpoint (the median time to sustained clinical improvement or resolution of the nine above-mentioned major symptoms as of day 14)Back to article page